Medtronic plc has successfully closed a public offering of €1.5 billion in senior notes, enhancing its financial strategy for upcoming obligations. On September 29, 2025, the company announced that its wholly-owned indirect subsidiary, Medtronic, Inc., concluded the registered public offering, which comprised two components: €750 million of senior notes due 2030 with a 2.950% interest rate and €750 million of senior notes due 2045 at 4.200%.
The offering will provide Medtronic, Inc. with approximately €1.49 billion in net proceeds after accounting for underwriting discounts and related expenses. These funds are intended to be used primarily to repay existing senior notes, specifically the 0.000% notes due in 2025 and the 2.625% notes also due in 2025.
Details of the Offering
The obligations under the notes are fully guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary and the indirect parent of Medtronic, Inc. The notes were offered under a prospectus dated March 3, 2023, which is available through the U.S. Securities and Exchange Commission’s EDGAR database. Interested parties can also obtain copies of the prospectus by contacting the joint book-running managers: Deutsche Bank AG, London Branch at +1 800-503-4611 and Goldman Sachs & Co. LLC at +1 866-471-2526.
Medtronic is headquartered in Galway, Ireland, and is recognized as a leading global healthcare technology company. Its mission focuses on alleviating pain, restoring health, and extending life, encapsulating its commitment to tackling significant health challenges. With a workforce of over 95,000 across more than 150 countries, Medtronic develops technologies that address 70 different health conditions, including cardiac devices and surgical tools.
The company emphasizes its innovative approach, stating that its diverse knowledge and commitment to care drive the transformation of lives every second of the day.
Looking Ahead
Medtronic’s announcement includes forward-looking statements regarding the expected use of proceeds from this offering. As noted, all statements beyond historical facts may be deemed forward-looking and involve risks. Investors are encouraged to review the “Risk Factors” section of the prospectus for detailed information, as well as Medtronic’s filings with the SEC, which outline potential risks associated with the company’s operations and financial strategies.
The completion of this offering positions Medtronic favorably for managing its financial obligations while continuing to focus on its mission of advancing healthcare through innovative solutions.